Search

Arthur L. Corbin

Examiner (ID: 24)

Most Active Art Unit
1302
Art Unit(s)
1794, 1302, 1761
Total Applications
1985
Issued Applications
1221
Pending Applications
190
Abandoned Applications
573

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17981282 [patent_doc_number] => 20220347318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => METHODS AND COMPOSITIONS FOR THE EXPRESSION OF CONSTITUTIVELY ACTIVE RAP1A FROM A VMD2 PROMOTER [patent_app_type] => utility [patent_app_number] => 17/763767 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763767 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/763767
METHODS AND COMPOSITIONS FOR THE EXPRESSION OF CONSTITUTIVELY ACTIVE RAP1A FROM A VMD2 PROMOTER Sep 24, 2020 Pending
Array ( [id] => 16711921 [patent_doc_number] => 20210079068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => ANTIBODY GENE THERAPY FOR TREATMENT AND PREVENTION OF INFECTION BY RABIES LYSSAVIRUS [patent_app_type] => utility [patent_app_number] => 17/024424 [patent_app_country] => US [patent_app_date] => 2020-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17024424 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/024424
ANTIBODY GENE THERAPY FOR TREATMENT AND PREVENTION OF INFECTION BY RABIES LYSSAVIRUS Sep 16, 2020 Abandoned
Array ( [id] => 16726521 [patent_doc_number] => 20210093668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/021526 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17021526 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/021526
NUCLEIC ACID CONSTRUCTS COMPRISING GENE EDITING MULTI-SITES AND USES THEREOF Sep 14, 2020 Abandoned
Array ( [id] => 17881167 [patent_doc_number] => 20220296644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/641688 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641688 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/641688
CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE Sep 9, 2020 Pending
Array ( [id] => 16686773 [patent_doc_number] => 20210069248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION [patent_app_type] => utility [patent_app_number] => 17/017670 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017670 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/017670
CA2 compositions and methods for tunable regulation Sep 9, 2020 Issued
Array ( [id] => 17007097 [patent_doc_number] => 20210238258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/017522 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21678 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17017522 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/017522
CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE Sep 9, 2020 Abandoned
Array ( [id] => 16885396 [patent_doc_number] => 20210171591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR) [patent_app_type] => utility [patent_app_number] => 17/016312 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17016312 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/016312
CODON OPTIMIZED NUCLEIC ACID ENCODING A RETINITIS PIGMENTOSA GTPASE REGULATOR (RPGR) Sep 8, 2020 Abandoned
Array ( [id] => 16791763 [patent_doc_number] => 20210121580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => Functionalized DNA Dendrimers For Gene Delivery To Cells [patent_app_type] => utility [patent_app_number] => 17/015925 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8952 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015925 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/015925
Functionalized DNA Dendrimers For Gene Delivery To Cells Sep 8, 2020 Abandoned
Array ( [id] => 16656012 [patent_doc_number] => 20210052648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => METHOD OF PRODUCING LEUKOCYTES USING PTPN2 INHIBITION FOR ADOPTIVE CELL TRANSFER [patent_app_type] => utility [patent_app_number] => 17/014737 [patent_app_country] => US [patent_app_date] => 2020-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17014737 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/014737
METHOD OF PRODUCING LEUKOCYTES USING PTPN2 INHIBITION FOR ADOPTIVE CELL TRANSFER Sep 7, 2020 Abandoned
Array ( [id] => 16484265 [patent_doc_number] => 20200377866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => COMPOSITIONS USEFUL IN TREATMENT OF ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY [patent_app_type] => utility [patent_app_number] => 16/995572 [patent_app_country] => US [patent_app_date] => 2020-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995572 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/995572
Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency Aug 16, 2020 Issued
Array ( [id] => 16686872 [patent_doc_number] => 20210069347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => GENE AUGMENTATION THERAPIES FOR INHERITED RETINAL DEGENERATION CAUSED BY MUTATIONS IN THE PRPF31 GENE [patent_app_type] => utility [patent_app_number] => 16/992689 [patent_app_country] => US [patent_app_date] => 2020-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16992689 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/992689
GENE AUGMENTATION THERAPIES FOR INHERITED RETINAL DEGENERATION CAUSED BY MUTATIONS IN THE PRPF31 GENE Aug 12, 2020 Abandoned
Array ( [id] => 19778519 [patent_doc_number] => 12227543 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-18 [patent_title] => Ancestral virus sequences and uses thereof [patent_app_type] => utility [patent_app_number] => 16/989454 [patent_app_country] => US [patent_app_date] => 2020-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 51 [patent_no_of_words] => 21247 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16989454 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/989454
Ancestral virus sequences and uses thereof Aug 9, 2020 Issued
Array ( [id] => 16570649 [patent_doc_number] => 20210009655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS [patent_app_type] => utility [patent_app_number] => 16/983977 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44822 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983977 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/983977
METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS Aug 2, 2020 Abandoned
Array ( [id] => 16671320 [patent_doc_number] => 20210060083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/925276 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925276 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/925276
METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF Jul 8, 2020 Abandoned
Array ( [id] => 16571000 [patent_doc_number] => 20210010006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => INCREASED NUCLEIC ACID-GUIDED CELL EDITING VIA A LEXA-RAD51 FUSION PROTEIN [patent_app_type] => utility [patent_app_number] => 16/917905 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16917905 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/917905
INCREASED NUCLEIC ACID-GUIDED CELL EDITING VIA A LEXA-RAD51 FUSION PROTEIN Jun 30, 2020 Abandoned
Array ( [id] => 20414358 [patent_doc_number] => 12497631 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Use of microvesicles in the treatment of medical conditions [patent_app_type] => utility [patent_app_number] => 16/909420 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 5948 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909420 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/909420
Use of microvesicles in the treatment of medical conditions Jun 22, 2020 Issued
Array ( [id] => 18733554 [patent_doc_number] => 11802277 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Thermostable Cas9 nucleases [patent_app_type] => utility [patent_app_number] => 16/906741 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 5 [patent_no_of_words] => 13539 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16906741 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/906741
Thermostable Cas9 nucleases Jun 18, 2020 Issued
Array ( [id] => 16341663 [patent_doc_number] => 20200306313 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION [patent_app_type] => utility [patent_app_number] => 16/900178 [patent_app_country] => US [patent_app_date] => 2020-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16900178 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/900178
METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION Jun 11, 2020 Abandoned
Array ( [id] => 17828559 [patent_doc_number] => 20220265863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF DBA USING GATA1 GENE THERAPY [patent_app_type] => utility [patent_app_number] => 17/612465 [patent_app_country] => US [patent_app_date] => 2020-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33888 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17612465 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/612465
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DBA USING GATA1 GENE THERAPY Jun 7, 2020 Pending
Array ( [id] => 16310833 [patent_doc_number] => 20200289571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY [patent_app_type] => utility [patent_app_number] => 16/885882 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16885882 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/885882
TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY May 27, 2020 Abandoned
Menu